Become A Featured Company

Future Farm is Rapidly Expanding Hemp Farm to Become One of the Largest in North America

Ryan Allway

December 22nd, 2017

Exclusive, News, Top Story

The cannabis industry is projected to exceed $50 billion in size by 2026, according to Cowen & Co., driven by the legalization of recreational marijuana throughout the United States. While recreational marijuana draws the most attention, the medical cannabis market could become a major contributor to the pharmaceutical industry over the coming years. Investors may want to keep a close eye on these trends and the companies best positioned to profit.

In this article, we will look at Future Farm Technologies Inc. (CSE: FFT) (OTCQB: FFRMF) and how it’s positioning itself to capitalize on demand from across the spectrum.

Cannabinoid Pharmaceuticals

The market for cannabinoid-based pharmaceuticals is projected to grow from $2 billion in 2020 to more than $50 billion by 2029, according to Statista, driven by increasing interest among pharmaceutical companies. While GW Pharmaceuticals plc (NASDAQ: GWPH) and Insys Therapeutics Inc.(NASDAQ: INSY) may be the most widely known companies in the space, many smaller companies have development-stage programs in the works.

Cannabinoid compounds, like cannabidiol (CBD), have demonstrated promise in treating many different underlying medical conditions without the side-effects of traditional pharmaceutical drugs. According to Google Scholar, there have been more than 2,000 papers published about CBD this year alone. Many companies have also become increasingly interested in the therapeutic potential for the cannabinoid, as evidenced by the more than 1,600 U.S. patents that have been issued mentioning CBD. For example, GW Pharmaceuticals’ Sativex® has been shown to be effective in treating central and peripheral neuropathic pain, rheumatoid arthritis, and cancer pain in numerous randomized clinical trials and has far fewer side effects than addictive opioids.

The traditional pharmaceutical industry has largely steered clear of the cannabinoid-based industry due to the legal status of cannabis in the United States. With many of these companies facing so-called patent cliffs over the coming years, and cannabis legalization taking hold across the U.S., smaller companies with promising clinical programs could see interest on the part of larger pharmaceutical companies looking to expand their portfolios. Cannabinoids are being studied for treatment of many multi-billion dollar conditions including psoriasis/skin conditions, epilepsy, Parkinson’s disease, inflammation, and pain.

Future Farm’s Unique Position

Future Farm Technologies is laying the groundwork to supply the cannabinoids for this expanding market. Though cannabis is federally illegal, the hemp version of the plant is not. Hemp provides CBD and other cannabinoids, it just needs to be grown with those characteristics emphasized to produce the maximum amount of the right type of cannabinoids. Future Farm is partnered with one of the worlds’ leading agro-biotechnology companies, Rahan Meristem Ltd., to create and clone the hemp plants with just such characteristics.

The company also features a closed-loop liquid-liquid phase extraction system that can draw out the cannabinoids from the hemp plant efficiently and effectively. The extracts are a fast-growing segment of both the medical and adult-use marijuana sectors to be sure, offering Future Farm a potentially lucrative revenue stream. These extracts can also be used to supply the ever-increasing amount of cannabinoid pharmaceutical research.

Expanding Footprint in Hemp

With the ability to create and replicate hemp plants with the desired cannabinoid profile, as well as the technology to extract those cannabinoids, Future Farm set about securing a hemp supply. The company recently announced that it has signed a lease agreement for 100-acres in Maine, which doubles its previously announced purchase of 120 acres of a licensed industrial hemp farm. As part of the agreement, the company has an option to lease up to an additional 1,000 acres from the landlord, which creates an enormous market opportunity as demand for hemp and its extracts rises over time.

Management is preparing to setup a clone operation, which will leverage vertical farming technology to supply over 200,000 clones to the farm next year. These hemp-based clones will be grown under its Scorpion LED grow lights to help save on electricity costs and further leverage its existing in-house technologies. The lease agreement also provides all other farming equipment needed to commence hemp farming activities.

“This lease agreement positions us in the hemp farming and CBD business for growing, researching, developing, and selling organic hemp and CBD oil, which contains a broad range of cannabinoids used to treat a growing population of CBD oil consumers,” said Future Farm CEO Bill Gildea. “We look forward to a very busy 2018 with our hemp and cannabis operations positioned on both coasts to meet the exploding demand of THC and CBD oil.”

Looking Ahead

Future Farm Technologies Inc. (CSE: FFT) (OTCQB: FFRMF) is well positioned to capitalize on the growing demand for CBD and other cannabinoids, not only in the pharmaceutical development industry but in the existing and growing consumer market, using its full-spectrum of in-house technologies. With the recent lease of an enormous hemp farm, investors may want to take a look at the stock as it gears up for commercial operations next year.

For more information, visit the company’s website at www.futurefarmtech.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading